A Phase 2 interventional study of PD 0332991 and letrozole in Breast Cancer, sponsored by Pfizer. Completed at 104 sites in 12 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-04.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.
Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 37th largest by enrollment, is the only one that started in 2008, is one of 62 in phase 2, and was the 1st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
American Society of Clinical Oncology · Sites in United States
Ages 60+
Region Örebro County · Sites in Finland, Greece, Italy and 3 more countries
Ages 70+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+ · Women only
Northwestern University · Sites in United States
Ages 18+
By country, each count listing its studies:
palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, palbociclib is the treatment under test here. Read study by study →
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 68 · Phase 3 21 · Phase 4 5
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 177 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 111 interventional studies. Of the 54 that completed or were terminated, 27 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 111 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 38th largest by enrollment of the 121 interventional ones that give a count, is one of 7 that started in 2008, is one of 43 in phase 2, and was the 44th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
13 of the studies testing palbociclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT02605486Memorial Sloan Kettering Cancer CenterPalbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) | 2026-11 |
| NCT02738866Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPalbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | 2026-12 |
| NCT07130643Xinhong Wu, PhDEfficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer | 2026-12-20 |
| NCT03573648Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNeoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 111 studies testing palbociclib in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
letrozole + PD 0332991
Drug: PD 0332991 · Drug: letrozole
letrozole
Drug: letrozole
125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
2.5 mg/d tablets orally on a continuous regimen
2.5 mg/d tablets orally on a continuous regimen
Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Maximum treatment duration (approximately 55 months)
Number of Participants With Treatment-Related Adverse Events at Phase 1
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Maximum treatment duration (approximately 55 months)
Number of Participants With Dose Limiting Toxicities at Phase 1
Dose limiting toxicity was defined as any of the following TEAEs occurring during the second cycle of treatment and possibly attributable to the combination of letrozole plus Palbociclib: 1. Grade 4 hematologic toxicity (including platelets \<25,000/μL, ANC \<500/μL). 2. Grade 3 neutropenia associated with a documented infection or fever ≥38.5°C. 3. Grade ≥3 non-hematologic toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea, hypertension). 4. Delay by ≥1 week in receiving the next scheduled dose of either study treatment due to persisting treatment-related toxicities (platelet count \<50,000/μL; ANC \<1,000/μL; nonhematologic toxicities of Grade ≥3 severity). 5. Inability to deliver at least 80% of the planned Palbociclib or letrozole doses during Cycle 2 due to toxicity possibly attributable to the study treatment.
Time frame: Cycle 2 (4 weeks)
Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment
PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Weeks or Months) = (first event date minus randomization or the first dose date plus 1) divided by 7 (or 30.44 if in months). PFS is usually characterized by the median, 25% percentile,75% percentile and their 95% Confidence Intervals (CIs).
Time frame: From randomization date to date of first documentation of progression or death (assessed up to 41 months)
Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.
Time frame: From Baseline up to end of study (assessed up to 55 months)
Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1
CBR is defined as a confirmed CR, confirmed PR, or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persisted on repeat imaging \>= 4 weeks after initial response.
Time frame: From Baseline up to end of study (assessed up to 55 months)
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
Time frame: Cycle 1 Day 14, and Cycle 2 Day 14
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
Time frame: Cycle 1 Day 14, and Cycle 2 Day 14
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
Time frame: Cycle 1 Day 14, and Cycle 2 Day 14
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
Time frame: Cycle 1 Day 14, and Cycle 2 Day 14
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
Time frame: Cycle 1 Day 14, and Cycle 2 Day 14
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
Time frame: Cycle 1 Day 14, and Cycle 2 Day 14
Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1
On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.
Time frame: Cycle 2 Day 14, Cycle 2 Day 28
Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1
On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.
Time frame: Cycle 2 Day 14, and Cycle 2 Day 28
Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1
On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.
Time frame: Cycle 2 Day 14, and Cycle 2 Day 28
Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval at Phase 1
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized.
Time frame: Cycle 1 Day 1 prior to dosing, Cycle 1 Day 14 (2, 4 [prior to meal], 8, 24, 48, and 96 hours after dosing of Palbociclib), Cycle 2 Day 1 and Day 14 (prior to and 4 hours after dosing of letrozole)
Overall Survival (OS) at Phase 2
Time in weeks or months from randomization to date of death due to any cause. OS was calculated as (the death date or last known alive date (if death date unavailable) minus the date of randomization plus 1) divided by 7 or 30.44 if in months.
Time frame: From randomization until death (assessed up to 86 months)
Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.
Time frame: From randomization up to the end of treatment (approximately 41 months)
Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment
Percentage of participants with objective response based assessment of confirmed CR or PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. Measurable disease referred to the lesions that was accurately measured in at least 1 dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10-16 mm with spiral computer tomography scan (depending on reconstruction interval). Clinical lesions were only be considered measurable when they were superficial (eg, skin nodules, palpable lymph nodes).
Time frame: From randomization up to the end of treatment (approximately 41 months)
Duration of Response at Phase 2 - Investigator Assessment
Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization \[or first dose of study medication for non-randomized studies\] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).
Time frame: From randomization up to the end of treatment (approximately 41 months)
Number of Participants With CBR at Phase 2 - Investigator Assessment
CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST.
Time frame: From randomization up to the end of treatment (approximately 41 months)
Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment
Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization \[or first dose of study medication for non-randomized studies\] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).
Time frame: From randomization up to the end of treatment (approximately 41 months)
Change From Baseline in Modified Brief Pain Inventory in Pain Severity Scale (mBPI-sf) Questionnaire at Phase 2
The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "completely interferes").
Time frame: Baseline, End of treatment (approximately 41 months)
Change From Baseline in Modified Brief Pain Inventory in Pain Interference Scale (mBPI-sf) Questionnaire at Phase 2
The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "completely interferes").
Time frame: Baseline, End of treatment (approximately 41 months)
Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - p16/INK4A, CCND1
Tissue samples were used for retrospective biomarker analyses. For Phase 2 Part 2, the tissue samples were sent to a central laboratory for the assessment of participant selection biomarkers. For Phase 2 Part 1, the assessment of the biomarkers (CCND1 amplification and/or loss of p16) were performed retrospectively from the available samples.
Time frame: Screening visit (≤ 28 Days prior to dosing)
Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Ki67
Frequency of tumor tissue biomarker Ki67 was evaluated in across treatment groups.
Time frame: Screening visit (≤ 28 Days prior to dosing)
Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Tumor Retinoblastoma (RB) and CyclinD1
Presence or absence of tumor RB and CyclinD1 were evaluated. The following definitions of expression applied in the below table: Positive: any expression \>0 and Negative: any expression=0.
Time frame: Screening visit (≤ 28 Days prior to dosing)
Summary of Copy Number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) at Phase 2
Gene copy number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) were evaluated. This analysis was done for Phase 2 combined group.
Time frame: Screening visit (≤ 28 Days prior to dosing)
Percentage of Participants With Tumor Expression of CYP19A1 and CCND1 Genotypes at Phase 2
One 2-mL blood specimen was collected for the analysis of germline polymorphism in CYP19A1 and CCND1 genes. A single nucleotide polymorphism (SNP) rs4646 as defined in the National Center for Biotechnology Information (NCBI) database in the aromatase gene (CYP19A1) was analyzed. A germline polymorphism G/A870 (rs9344) in the CCND1 gene was analyzed.
Time frame: Screening visit (≤ 28 Days prior to dosing)
Number of Participants With TEAEs (All Causalities) at Phase 2
AE:any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.AEs included both serious and non-serious AEs.SAE:AE resulting in any of following outcomes/deemed significant and jeopardized participants or required treatment to prevent other AE outcomes for any other reason:death;initial or prolonged inpatient hospitalization;life-threatening experience (immediate risk of dying);persistent or significant disability/incapacity;congenital anomaly.Treatment emergent AEs:events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or worsened relative to pre-treatment state.AEs were graded as per the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and coded using Medical Dictionary for Regulatory Activities (MedDRA). Participants with AE of grade 3 or 4 and grade 5 were reported as Grade 3:Severe, Grade 4:Life threatening, Grade 5:Death related to AE.
Time frame: Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)
Number of Participants With Treatment-Related Adverse Events at Phase 2
AE: any untoward medical occurrence in a participant who received study drug. AEs included both serious and non-serious adverse events. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs: events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. Treatment related AEs: all AEs with causality related to treatment. Relatedness to drug was assessed by the investigator. AEs were graded according to the CTCAE version 3.0 and coded using the MedDRA. Number of participants with AE of grade 3 or 4 and with AE of grade 5 were reported as Grade 3: Severe, Grade 4: Life threatening, Grade 5: Death related to AE.
Time frame: Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)
This Phase 1/2, open-label, randomized study enrolled a total of 12 participants at 3 sites in the United States for Phase 1. Phase 1 participants received Palbociclib + Letrozole. In Phase 2, a total of 165 participants were randomized (84 in palbociclib plus letrozole arm and 81 in letrozole alone arm) at 50 sites in 12 countries.
| Milestone | Phase 1 (Palbociclib + Letrozole) | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) |
|---|---|---|---|
| Started | 12 | 84 | 81 |
| Treated | 12 | 83 | 77 |
| Completed | 0 | 2 | 2 |
| Not completed | 12 | 82 | 79 |
| Withdrew: Global deterioration of health status | 2 | 6 | 3 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Randomized not treated | 0 | 1 | 4 |
| Withdrew: Reason not specified | 1 | 0 | 2 |
| Withdrew: Adverse event | 0 | 13 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 6 | 5 |
| Withdrew: Objective progression or relapse | 8 | 55 | 62 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Phase 1 (Palbociclib + Letrozole) |
|---|---|
| Participants with AEs | 12 |
| Participants with SAEs | 2 |
| Participants with Grade 3 or 4 AEs | 11 |
| Participants with Grade 5 AEs | 0 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Phase 1 (Palbociclib + Letrozole) |
|---|---|
| Participants with AEs | 12 |
| Participants with SAEs | 0 |
| Participants with Grade 3 or 4 AEs | 11 |
| Participants with Grade 5 AEs | 0 |
Dose limiting toxicity was defined as any of the following TEAEs occurring during the second cycle of treatment and possibly attributable to the combination of letrozole plus Palbociclib: 1. Grade 4 hematologic toxicity (including platelets \<25,000/μL, ANC \<500/μL). 2. Grade 3 neutropenia associated with a documented infection or fever ≥38.5°C. 3. Grade ≥3 non-hematologic toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea, hypertension). 4. Delay by ≥1 week in receiving the next scheduled dose of either study treatment due to persisting treatment-related toxicities (platelet count \<50,000/μL; ANC \<1,000/μL; nonhematologic toxicities of Grade ≥3 severity). 5. Inability to deliver at least 80% of the planned Palbociclib or letrozole doses during Cycle 2 due to toxicity possibly attributable to the study treatment.
| Participants | Phase 1 (Palbociclib + Letrozole) |
|---|---|
| Grade 4 Neutropenia | 2 |
| <80% of doses due to elevated creatinine | 1 |
PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Weeks or Months) = (first event date minus randomization or the first dose date plus 1) divided by 7 (or 30.44 if in months). PFS is usually characterized by the median, 25% percentile,75% percentile and their 95% Confidence Intervals (CIs).
| Months | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment | 20.2 (13.8 to 27.5) | 10.2 (5.7 to 12.6) | 26.1 (11.2 to NA) | 5.7 (2.6 to 10.5) | 18.1 (13.1 to 27.5) | 11.1 (7.1 to 16.4) |
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.
| Percentage of participants | Phase 1 (Palbociclib + Letrozole) |
|---|---|
| Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1 | 33.3 (9.9 to 65.1) |
CBR is defined as a confirmed CR, confirmed PR, or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persisted on repeat imaging \>= 4 weeks after initial response.
| Percentage of participants | Phase 1 (Palbociclib + Letrozole) |
|---|---|
| Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1 | 83.3 (51.6 to 97.9) |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
| ng·hr/mL | Palbociclib Alone (Cycle 1 Day 14) | Palbociclib + Letrozole (Cycle 2 Day 14) |
|---|---|---|
| Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1 | 1982 ± 29 | 1933 ± 31 |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
| ng/mL | Palbociclib Alone (Cycle 1 Day 14) | Palbociclib + Letrozole (Cycle 2 Day 14) |
|---|---|---|
| Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1 | 115.8 ± 28 | 108.4 ± 29 |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
| Hour | Palbociclib Alone (Cycle 1 Day 14) | Palbociclib + Letrozole (Cycle 2 Day 14) |
|---|---|---|
| Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1 | 7.92 ± 28 | 7.92 ± 29 |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
| Hour | Palbociclib Alone (Cycle 1 Day 14) | Palbociclib + Letrozole (Cycle 2 Day 14) |
|---|---|---|
| Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1 | 28.81 ± 5.0462 | NA ± NA |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
| L/hr | Palbociclib Alone (Cycle 1 Day 14) | Palbociclib + Letrozole (Cycle 2 Day 14) |
|---|---|---|
| Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1 | 63.08 ± 29 | NA ± NA |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.
| L | Palbociclib Alone (Cycle 1 Day 14) | Palbociclib + Letrozole (Cycle 2 Day 14) |
|---|---|---|
| Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1 | 2583 ± 26 | NA ± NA |
On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.
| ng·hr/mL | Palbociclib + Letrozole (Cycle 2 Day 14) | Letrozole Alone (Cycle 2 Day 28) |
|---|---|---|
| Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1 | 1739 ± 30 | 1936 ± 35 |
On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.
| ng/mL | Palbociclib + Letrozole (Cycle 2 Day 14) | Letrozole Alone (Cycle 2 Day 28) |
|---|---|---|
| Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1 | 94.95 ± 27 | 104.0 ± 31 |
On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.
| Hour | Palbociclib + Letrozole (Cycle 2 Day 14) | Letrozole Alone (Cycle 2 Day 28) |
|---|---|---|
| Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1 | 2.00 ± 27 | 1.04 ± 31 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized.
| Participants | Phase 1 (Palbociclib + Letrozole) |
|---|---|
| QTcB - Change <30 | 9 |
| QTcB - 30 ≤ change <60 | 3 |
| QTcB - Change ≥60 | 0 |
| QTcF - Change <30 | 11 |
| QTcF - 30 ≤ change <60 | 1 |
| QTcF - Change ≥60 | 0 |
| QTcS - Change <30 | 8 |
| QTcS - 30 ≤ change <60 | 4 |
| QTcS - Change ≥60 | 0 |
Time in weeks or months from randomization to date of death due to any cause. OS was calculated as (the death date or last known alive date (if death date unavailable) minus the date of randomization plus 1) divided by 7 or 30.44 if in months.
| Months | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| Overall Survival (OS) at Phase 2 | 37.5 (31.4 to 47.8) | 34.5 (27.4 to 42.6) | 37.5 (27.6 to 58.8) | 33.3 (26.0 to 54.3) | 35.1 (28.1 to 47.8) | 35.7 (26.6 to 46.7) |
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.
| Percentage of participants | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment | 42.9 (32.1 to 54.1) | 33.3 (23.2 to 44.7) | 44.1 (27.2 to 62.1) | 25.0 (11.5 to 43.4) | 42.0 (28.2 to 56.8) | 38.8 (25.2 to 53.8) |
Percentage of participants with objective response based assessment of confirmed CR or PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. Measurable disease referred to the lesions that was accurately measured in at least 1 dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10-16 mm with spiral computer tomography scan (depending on reconstruction interval). Clinical lesions were only be considered measurable when they were superficial (eg, skin nodules, palpable lymph nodes).
| Percentage of participants | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment | 55.4 (42.5 to 67.7) | 39.4 (27.6 to 52.2) | 55.6 (35.3 to 74.5) | 34.8 (16.4 to 57.3) | 55.3 (38.3 to 71.4) | 41.9 (27.0 to 57.9) |
Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization \[or first dose of study medication for non-randomized studies\] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).
| Months | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| Duration of Response at Phase 2 - Investigator Assessment | 20.3 (13.4 to 25.8) | 11.1 (9.3 to 31.6) | 20.9 (6.2 to 25.8) | 10.8 (3.7 to 31.6) | 20.2 (13.0 to NA) | 14.8 (7.4 to NA) |
CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST.
| Percentage of participants | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| Number of Participants With CBR at Phase 2 - Investigator Assessment | 81.0 (70.9 to 88.7) | 58.0 (46.5 to 68.9) | 76.5 (58.8 to 89.3) | 43.8 (26.4 to 62.3) | 84.0 (70.9 to 92.8) | 67.3 (52.5 to 80.1) |
Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization \[or first dose of study medication for non-randomized studies\] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).
| Months | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment | 20.2 (13.8 to 27.5) | 10.2 (5.7 to 12.6) | 26.1 (11.2 to NA) | 5.7 (2.6 to 10.5) | 18.8 (13.1 to 27.5) | 11.1 (7.1 to 16.4) |
The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "completely interferes").
| Units on a scale | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| Pain at its worst in the last 24 hours | 0.6 ± 0.42 | 0.1 ± 0.42 | 0.2 ± 0.60 | 0.0 ± 0.89 | 1.2 ± 0.55 | 0.1 ± 0.43 |
| Pain at its least in the last 24 hours | 0.4 ± 0.27 | 0.4 ± 0.27 | 0.3 ± 0.31 | 0.7 ± 0.50 | 0.5 ± 0.40 | 0.2 ± 0.31 |
| Pain on the average | 0.2 ± 0.33 | 0.2 ± 0.34 | -0.1 ± 0.48 | 0.2 ± 0.64 | 0.4 ± 0.45 | 0.3 ± 0.40 |
| Pain right now | 0.3 ± 0.35 | 0.1 ± 0.36 | 0.1 ± 0.31 | 0.3 ± 0.66 | 0.3 ± 0.55 | 0.0 ± 0.43 |
| Pain Severity Scale | 0.4 ± 0.29 | 0.2 ± 0.32 | 0.0 ± 0.36 | 0.3 ± 0.62 | 0.6 ± 0.41 | 0.1 ± 0.36 |
The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "completely interferes").
| Units on a scale | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| General Activity | 1.1 ± 0.40 | 0.2 ± 0.31 | 1.0 ± 0.66 | 0.2 ± 0.58 | 1.2 ± 0.51 | 0.3 ± 0.37 |
| Mood | 0.8 ± 0.50 | 0.2 ± 0.36 | 0.6 ± 0.72 | -0.2 ± 0.62 | 1.0 ± 0.69 | 0.4 ± 0.44 |
| Walking ability | 0.8 ± 0.46 | 0.1 ± 0.35 | 1.0 ± 0.55 | 0.3 ± 0.63 | 0.7 ± 0.67 | 0.0 ± 0.43 |
| Normal work | 0.7 ± 0.48 | 0.3 ± 0.39 | 1.0 ± 0.53 | 0.2 ± 0.74 | 0.5 ± 0.71 | 0.4 ± 0.45 |
| Relations | 0.8 ± 0.32 | 0.8 ± 0.32 | 0.6 ± 0.34 | 0.6 ± 0.60 | 0.9 ± 0.47 | 0.8 ± 0.37 |
| Sleep | 0.6 ± 0.43 | 0.3 ± 0.35 | 0.1 ± 0.53 | 0.5 ± 0.63 | 0.9 ± 0.61 | 0.1 ± 0.42 |
| Enjoyment of life | 0.8 ± 0.46 | 0.6 ± 0.41 | 0.4 ± 0.34 | 0.2 ± 0.69 | 1.1 ± 0.71 | 0.8 ± 0.52 |
| Pain Interference Scale | 0.8 ± 0.34 | 0.4 ± 0.30 | 0.7 ± 0.42 | 0.3 ± 0.56 | 0.9 ± 0.48 | 0.4 ± 0.36 |
Tissue samples were used for retrospective biomarker analyses. For Phase 2 Part 2, the tissue samples were sent to a central laboratory for the assessment of participant selection biomarkers. For Phase 2 Part 1, the assessment of the biomarkers (CCND1 amplification and/or loss of p16) were performed retrospectively from the available samples.
| Participants | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|
| CCND1>=1.5 | 12 ± 0.66 | 9 ± 0.58 | 39 ± 0.51 | 44 ± 0.37 |
| p16/INK4A<0.8 | 0 ± 0.72 | 2 ± 0.62 | 19 ± 0.69 | 12 ± 0.44 |
| CCND1>=1.5 and p16/INK4A<0.8 | 0 ± 0.55 | 2 ± 0.63 | 8 ± 0.67 | 8 ± 0.43 |
Frequency of tumor tissue biomarker Ki67 was evaluated in across treatment groups.
| Participants | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| <=20% | 26 ± 0.40 | 31 ± 0.31 | 7 ± 0.66 | 16 ± 0.58 | 19 ± 0.51 | 15 ± 0.37 |
| >20% | 48 ± 0.50 | 40 ± 0.36 | 17 ± 0.72 | 10 ± 0.62 | 31 ± 0.69 | 30 ± 0.44 |
Presence or absence of tumor RB and CyclinD1 were evaluated. The following definitions of expression applied in the below table: Positive: any expression \>0 and Negative: any expression=0.
| Participants | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| CyclinD1 - Positive | 41 ± 0.40 | 32 ± 0.31 | 10 ± 0.66 | 16 ± 0.58 | 31 ± 0.51 | 16 ± 0.37 |
| CyclinD1 - Negative | 3 ± 0.50 | 3 ± 0.36 | 2 ± 0.72 | 0 ± 0.62 | 1 ± 0.69 | 3 ± 0.44 |
| RB - Positive | 41 | 32 | 10 | 16 | 31 | 16 |
| RB - Negative | 2 | 2 | 2 | 0 | 0 | 2 |
Gene copy number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) were evaluated. This analysis was done for Phase 2 combined group.
| Copy number | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) |
|---|---|---|
| CCND1 | 2.76 ± 1.875 | 2.73 ± 1.559 |
| p16/INK4A | 0.83 ± 0.224 | 0.87 ± 0.173 |
One 2-mL blood specimen was collected for the analysis of germline polymorphism in CYP19A1 and CCND1 genes. A single nucleotide polymorphism (SNP) rs4646 as defined in the National Center for Biotechnology Information (NCBI) database in the aromatase gene (CYP19A1) was analyzed. A germline polymorphism G/A870 (rs9344) in the CCND1 gene was analyzed.
| Percentage of participants | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| CYP19A1 - A/A Genotype | 7.9 ± 0.42 | 5.4 ± 0.42 | 10.0 ± 0.60 | 10.7 ± 0.89 | 6.5 ± 0.55 | 2.2 ± 0.43 |
| CYP19A1 - C/A Genotype | 34.2 ± 0.27 | 36.5 ± 0.27 | 33.3 ± 0.31 | 42.9 ± 0.50 | 34.8 ± 0.40 | 32.6 ± 0.31 |
| CYP19A1 - C/C Genotype | 57.9 ± 0.33 | 58.1 ± 0.34 | 56.7 ± 0.48 | 46.4 ± 0.64 | 58.7 ± 0.45 | 65.2 ± 0.40 |
| CCND1 - A/A Genotype | 26.3 ± 0.35 | 28.4 ± 0.36 | 33.3 ± 0.31 | 39.3 ± 0.66 | 21.7 ± 0.55 | 21.7 ± 0.43 |
| CCND1 - G/A Genotype | 47.4 ± 0.29 | 47.3 ± 0.32 | 43.3 ± 0.36 | 42.9 ± 0.62 | 50.0 ± 0.41 | 50.0 ± 0.36 |
| CCND1 - G/G Genotype | 26.3 | 24.3 | 23.3 | 17.9 | 28.3 | 28.3 |
AE:any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.AEs included both serious and non-serious AEs.SAE:AE resulting in any of following outcomes/deemed significant and jeopardized participants or required treatment to prevent other AE outcomes for any other reason:death;initial or prolonged inpatient hospitalization;life-threatening experience (immediate risk of dying);persistent or significant disability/incapacity;congenital anomaly.Treatment emergent AEs:events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or worsened relative to pre-treatment state.AEs were graded as per the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and coded using Medical Dictionary for Regulatory Activities (MedDRA). Participants with AE of grade 3 or 4 and grade 5 were reported as Grade 3:Severe, Grade 4:Life threatening, Grade 5:Death related to AE.
| Participants | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| Participants with AEs | 83 | 66 | 33 | 25 | 50 | 41 |
| Participants with SAEs | 22 | 6 | 10 | 2 | 12 | 4 |
| Participants with Grade 3 or 4 AEs | 70 | 19 | 29 | 5 | 41 | 14 |
| Participants with Grade 5 AEs | 1 | 0 | 0 | 0 | 1 | 0 |
AE: any untoward medical occurrence in a participant who received study drug. AEs included both serious and non-serious adverse events. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs: events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. Treatment related AEs: all AEs with causality related to treatment. Relatedness to drug was assessed by the investigator. AEs were graded according to the CTCAE version 3.0 and coded using the MedDRA. Number of participants with AE of grade 3 or 4 and with AE of grade 5 were reported as Grade 3: Severe, Grade 4: Life threatening, Grade 5: Death related to AE.
| Participants | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|
| Participants with AEs | 78 | 33 | 32 | 13 | 46 | 20 |
| Participants with SAEs | 1 | 0 | 0 | 0 | 1 | 0 |
| Participants with Grade 3 or 4 AEs | 57 | 2 | 25 | 0 | 32 | 2 |
| Participants with Grade 5 AEs | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Baseline up to 28 days after last dose of study drug (for a maximum of 86 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 (Palbociclib + Letrozole) | 0/12 (0%) | 2/12 (16.7%) | 12/12 (100%) |
| Phase 2 (Palbociclib + Letrozole) | 3/83 (3.6%) | 22/83 (26.5%) | 83/83 (100%) |
| Phase 2 (Letrozole) | 1/77 (1.3%) | 6/77 (7.8%) | 57/77 (74%) |
| Ph2P1 (Palbociclib + Letrozole) | 1/33 (3%) | 10/33 (30.3%) | 33/33 (100%) |
| Ph2P1 (Letrozole) | 0/29 (0%) | 2/29 (6.9%) | 22/29 (75.9%) |
| Ph2P2 (Palbociclib + Letrozole) | 2/50 (4%) | 12/50 (24%) | 50/50 (100%) |
| Ph2P2 (Letrozole) | 1/48 (2.1%) | 4/48 (8.3%) | 35/48 (72.9%) |
| Event | Phase 1 (Palbociclib + Letrozole) | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/12 | 4/83 | 0/77 | 4/33 | 0/29 | 0/50 | 0/48 |
| PainGeneral disorders | 1/12 | 1/83 | 0/77 | 1/33 | 0/29 | 0/50 | 0/48 |
| NauseaGastrointestinal disorders | 1/12 | 0/83 | 0/77 | 0/33 | 0/29 | 0/50 | 0/48 |
| VomitingGastrointestinal disorders | 1/12 | 0/83 | 0/77 | 0/33 | 0/29 | 0/50 | 0/48 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/12 | 2/83 | 0/77 | 0/33 | 0/29 | 2/50 | 0/48 |
| IleusGastrointestinal disorders | 0/12 | 0/83 | 1/77 | 0/33 | 1/29 | 0/50 | 0/48 |
| Subcutaneous emphysemaSkin and subcutaneous tissue disorders | 0/12 | 0/83 | 1/77 | 0/33 | 1/29 | 0/50 | 0/48 |
| Gastrointestinal disorderGastrointestinal disorders | 0/12 | 1/83 | 0/77 | 1/33 | 0/29 | 0/50 | 0/48 |
| AstheniaGeneral disorders | 0/12 | 1/83 | 0/77 | 1/33 | 0/29 | 0/50 | 0/48 |
| Chest painGeneral disorders | 0/12 | 1/83 | 0/77 | 1/33 | 0/29 | 0/50 | 0/48 |
| Event | Phase 1 (Palbociclib + Letrozole) | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Ph2P1 (Palbociclib + Letrozole) | Ph2P1 (Letrozole) | Ph2P2 (Palbociclib + Letrozole) | Ph2P2 (Letrozole) |
|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 11/12 | 62/83 | 4/77 | 26/33 | 1/29 | 36/50 | 3/48 |
| FatigueGeneral disorders | 10/12 | 34/83 | 18/77 | 14/33 | 7/29 | 20/50 | 11/48 |
| LeukopeniaBlood and lymphatic system disorders | 8/12 | 36/83 | 3/77 | 16/33 | 1/29 | 20/50 | 2/48 |
| DiarrhoeaGastrointestinal disorders | 6/12 | 18/83 | 9/77 | 9/33 | 2/29 | 9/50 | 7/48 |
| NauseaGastrointestinal disorders | 6/12 | 25/83 | 11/77 | 12/33 | 7/29 | 13/50 | 4/48 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/12 | 22/83 | 14/77 | 9/33 | 5/29 | 13/50 | 9/48 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/12 | 14/83 | 7/77 | 4/33 | 3/29 | 10/50 | 4/48 |
| AnaemiaBlood and lymphatic system disorders | 4/12 | 29/83 | 3/77 | 13/33 | 0/29 | 16/50 | 3/48 |
| HeadacheNervous system disorders | 4/12 | 12/83 | 8/77 | 6/33 | 3/29 | 6/50 | 5/48 |
| VomitingGastrointestinal disorders | 3/12 | 15/83 | 3/77 | 9/33 | 2/29 | 6/50 | 1/48 |
Analysis was done on participants who received at least one dose of study drug.
| Age, Customized(Participants) | Phase 1 (Palbociclib + Letrozole) | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Total |
|---|---|---|---|---|
| <18 Years | 0 | 0 | 0 | 0 |
| 18-44 Years | 1 | 2 | 4 | 7 |
| 45-64 Years | 6 | 45 | 38 | 89 |
| >= 65 Years | 5 | 37 | 39 | 81 |
| Sex: Female, Male(Participants) | Phase 1 (Palbociclib + Letrozole) | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Total |
|---|---|---|---|---|
| Female | 12 | 84 | 81 | 177 |
| Male | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase 1 (Palbociclib + Letrozole) | Phase 2 (Palbociclib + Letrozole) | Phase 2 (Letrozole) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 6 | 4 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 2 |
| White | 11 | 76 | 72 | 159 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 4 | 6 |
Showing the first 100 of 104 sites across 12 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2008 to primary completion in Nov 2013, 62 months.
Results were first posted in Mar 2015, 1 year 3 months after primary completion. A results delay was requested in Dec 2014.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 62 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palbociclib